This article outlines the new NICE recommendations on continuous glucose monitoring in children and young people with diabetes, as well as the recommendations’ rationale and possible impact on clinical practice.
Following the latest NICE advice, more than 250,000 people living with type 1 diabetes are set to be offered new technology to help them manage their condition. Use of flash monitoring is also extended to adults with type 2 diabetes on insulin therapy.
The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us